5-Fluorouracil with or without Interferon-β for Colorectal Cancer
Author Information
Author(s): Villar-Grimalt A, Candel M T, Massuti B, Lizón J, Sánchez B, Frau A, Gorostidi B, Goedkoop R
Hypothesis
Does the addition of human interferon-β improve the efficacy of 5-fluorouracil in treating advanced colorectal cancer?
Conclusion
The addition of interferon-β to 5-fluorouracil significantly improved response rates, time to progression, and survival without significantly increasing toxicity.
Supporting Evidence
- The addition of IFN-β improved response rate from 4.5% to 33.3%.
- Median time to progression increased from 4.2 months to 7.2 months with the combination therapy.
- Median survival time improved from 7.2 months to 15.9 months with the addition of IFN-β.
- More patients receiving monotherapy discontinued treatment due to disease progression.
Takeaway
This study found that adding a medicine called interferon-β to another medicine, 5-fluorouracil, helps people with advanced colorectal cancer live longer and feel better.
Methodology
Patients were randomized to receive either 5-FU alone or in combination with IFN-β, with treatment lasting for 52 weeks or until disease progression.
Limitations
The study was limited to chemotherapy-naive patients and may not be generalizable to all colorectal cancer patients.
Participant Demographics
Chemotherapy-naive patients with unresectable, advanced colorectal carcinoma.
Statistical Information
P-Value
P = 0.021
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website